Sutro Biopharma, Inc.
Clinical trials sponsored by Sutro Biopharma, Inc., explained in plain language.
-
New hope for tough ovarian cancer? trial tests targeted drug vs standard chemo
Disease control TerminatedThis study tested a new drug, luveltamab tazevibulin, against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum-based treatment. The drug targets a protein called FOLR1 found on cancer cells. The trial was terminated early, so results …
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
Ovarian cancer drug combo trial halted early
Disease control TerminatedThis early-stage trial tested a new drug (STRO-002) combined with bevacizumab in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the best dose. The study was terminated, so results are limited.
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC